Phorbol myristate acetate (PMA) induces the expression of megakaryocyte and/or platelet proteins during terminal differentiation of human erythroleukemia (HEL) cells. However, it is not established whether megakaryocytic differentiation is accompanied by the downregulation of the major erythroid transcription factor GATA-1 and the concomitant loss of the erythrocytic phenotype. Studies of the molecular mechanism of PMA-induced differentiation in HEL cells showed that when HEL cells are treated with PMA, they dramatically decrease the expression of the erythroid-specific gene glycophorin A at the mRNA level but apparently not at the steady-state protein level. In addition, a gel mobility shift assay was used to demonstrate that GATA-1, a major erythroid transcription factor normally present at high levels in HEL cells is downregulated after PRIMARY DEFECT of leukemia cells is their inability
treatment with PMA. In contrast, the DNA-binding activities of transcription factors AP-1 and SP-1 are upregulated by PMA treatment of HEL cells. Furthermore, Northern blot analysis shows that PMA also downregulates the steadystate level of GATA-1 mRNA in HEL cells. The coordinated negative regulation of glycophorin A mRNA and GATA-1 expression after PMA treatment suggests that downregulation of GATA-1 expression may be partially responsible for the loss of the erythroid phenotype during megakaryocytic differentiation. The reported data also suggest that GATA-1 activity may not be essential for obtaining megakaryocytic phenotype during terminal differentiation in HEL cells. products are normally expressed in leukemia cells of various lineages. However, it is unclear how the alteration of the expression of these genes affects lineage-specific differentiation of a particular leukemia cell line. One hypothesis states that modulation of the expression or activities of lineage-restricted factors and/or in particular lineage-restricted transcription factor(s) may be a key step in regulating leukemia cell differentiation.
GATA-1 is a lineage-specific transcription factor predominantly expressed in erythroid cells, and expression of genes characteristic of erythroid lineage are under its GATA-1 gene expression appears to be developmentally controlled, and its expression correlates with the complex patterns of globin gene expression. For example, in a developing mouse embryo, GATA-1 expression precedes and parallels the levels of globin mRNA.22 In addition, in Xenopus luevis embryogenesis, GATA-1 is expressed as early as the gastrula stage. Expression of GATA-I precedes any globin expression and blood island formation, suggesting that GATA-1 may be also involved in commitment of the mesoderm to form hematopoietic organs. 23 It has been demonstrated by the gene-disruption approach that GATA-1 is absolutely required for erythroid d e~e l o p m e n t .~~ However, it remains unclear how GATA-1 gene expression or its activity is regulated during hematopoiesis or erythroid commitment and differentiation. In addition, although mature megakaryocytes express the GATA-1 f a c t~r z~.~~ and the 5' regulatory region of several genes characteristic of the megakaryocytic lineage contain the GATA factor-binding motif,27 gene-disruption experiments have not documented any role for the transcription factor in megakaryopoie~is.~~ Because the HEL cell line can be induced by PMA to express several megakaryocytic-specific genes and undergo a megakaryocytic terminal differentiation,' we asked whether the PMA-induced megakaryocytic differentiation is negatively correlated with erythroid marker gene expression. We observed that following PMA treatment, glycophorin A expression in HEL cells was dramatically downregulated at the mRNA level but not at the steady-state protein level, and that HEL cells constitutively expressed GATA-1 mRNA and high levels of cytoplasmic and nuclear GATA-1 activity that were significantly down-regulated during PMA-induced megakaryocytic differentiation.
MATERIALS AND METHODS
HEL and K562 cell lines and cDNAs coding for human glycophorin A and platelet-derived growth factor p chain (PDGFp) were purchased from American Type Culture Collection (Rockville, MD was a gift from Bristol-Myers laboratory (Wallingford, CT) and was dissolved in 100% EtOH and diluted at least 1,000-fold when added to culture medium. HEL and K562 cells were grown in suspension culture in RPMI 1640 medium containing 10% fetal calf serum and penicillin (100 pg/mL) and streptomycin (50 pg/mL). Cells were passed twice each week, seeding at a concentration of 1 to 2 X IO5/ mL. For treatment with various agents, exponential growing HEL or K562 cells were collected ( I ,200 g X 10 minutes) and resuspended in fresh culture medium containing PMA (100 nmol/L), okadaic acid (5 nmol/L), hemin (60 pmol/L), or ACL (60 nmol/L) at a density about 5 X IO5 mL and cultured for 2 days.
Total RNA was isolated from treated HEL or K562 cells using the guanidine/HCl procedure. 29 Equal amounts (10 pg) of total RNA were sequentially diluted by a factor of 2 using buffer conditions as described," and the diluted RNA was directly applied to nitrocellulose using a dot blot apparatus. Dot blots were hybridized overnight with a glycophorin A or PDGFp cDNA probe labeled with ',P, washed after hybridization, and autoradiographed. Dot blots were quantitated by densitometric scanning. Northern blotting analysis was performed as de~cribed.~' Northern blots were hybridized with a GATA-1 cDNA probe labeled with 32P, washed after hybridization, and autoradiographed. Hybridization and washing conditions were as described?'
A small-scale isolation method was adapted from the procedure described by Nicolas et aI?* Cells (1 X IO7) were collected (2,000 g X 10 minutes) and rinsed once in 1 mL of phosphate-buffered saline (PBS). Cell pellets were then resuspended in I mL of lysis buffer (IO mmol/L TRIS-HCI, pH 7.5; 5 mmol/L MgCI,, 0.5% [vol/vol] triton X 100, 0.1% [vol/vol] NP-40) and left on ice for 5 minutes. Supernatant (12,OOOg X 5 minutes) of cell lysates was discarded and the nuclear fraction resuspended in twice the pellet volume of low-salt buffer (20 mmol/L HEPES, pH 7.9; 25% [vol/vol] glycerol; 1.5 mmol MgCI2; 20 mmol/ L KCI; 0.2 mmol/L EDTA; 0.2 mmol/L PMSF 0.5 mmol/L dithiothreitol [DTT]). Following slow addition of one pellet volume of high-salt buffer (low-salt buffer with 1.2 mol/L KCI) to the resus-
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pended nuclei, nuclear proteins were extracted on ice for 30 minutes.
Nuclear suspension was centrifuged (12,OOOg X 15 minutes) and the supernatant collected and dialyzed (dialysis tubing exclusion size 3,500 dalton) in dialysis buffer (20 mmol/L HEPES, pH 7.9; 20% [vol/vol] glycerol; 100 mmol/L KCI; 0.2 mmol/L EDTA; 0.2 mmol/L PMSF: 0.5 pg/mL aprotinin; 0.5 pg/mL leupeptin; 0.5 mmol/L DTT) for 3 hours. After centrifuging ( I2,OOOg X 15 minutes), the soluble fraction was measured for protein concentration with the Bradford proce-durcg2 Cytosolic protein isolation was carried out as follows: Cells (5 to 10 X IO7), rinsed once in I O mL of the PBS saline, were resuspended in 0.5 mL of hypotonic buffer ([IO mmol/L HEPES/KOH, pH 7.4; IO mmol/L KC1; 1.5 mmol/L MgCI2; 0.1 mmol/L EGTA; 0.5 mmol/L PMSF 1 pg/mL leupeptin; 0.1% [vol/vol] NP-401 and kept on ice for I O minutes. Cells were further lysed by homogenizing (16 strokes) and the cytosolic fraction (12,OOOg X 10 minutes) was saved and dialyzed as above. Typically, IO pg of nuclear proteins or 30 pg of cytosol proteins was used for each gel mobility shift assay.
Band shift assays are performed essentially as described. 33 Briefly, for each assay, nuclear ( I O pg) or cytosolic (30 pg) protein extracts were incubated in a total volume of 15 pL of a buffer mixture (10 mmol/L HEPES, pH 7.9; 10% [vol/vol] glycerol; 50 mmol/L KCI; 0.1 mmol/L EDTA; 0. I mmol/L PMSF; 0.25 mmol/ L DTT; 1 mmol/L MgCI,; 2 pg bovine serum albumin; 0.5 pg poly(d1-dC); 2-4 X lo4 cpm of a 32P-labeled oligonucleotide with a specific activity of 1 X lo5 cpm/ng). The 32P-DNA/protein complexes were resolved from unbound DNA probe by electrophoresis in 4% polyacrylamide gels (PAGE) run in a low ionic strength buffer (8 mmol/ L TRIS-HCI, pH 7.9; 3.3 mmol/L sodium acetate, pH 7.9; 1 mmol/ L EDTA). The gels were dried under vacuum followed by autoradiography using Fuji RX x-ray films. The oligonucleotide used for detecting GATA-I activity was a 34-mer DNA fragment containing the GATA-I-binding site from mouse a-globin promoter (SGGG-AGGTGATCCAGGCAACTGATAAGGATTCCCAY) as initially described.28 Two extra guanylyl residues were added at the 5' end to serve as a template for labeling with '2P-dCTP.
Complementary oligonucleotides (40 pg/mL in 250 mmol/L NaC1) were denatured at 95°C for 3 minutes followed by slow cooling to room temperature. "Plabeling of the annealed oligonucleotide fragments (200 ng) was achieved by a filling-in reaction with Klenow fragment of DNA polymerase 1 in a 100 pL reaction mixture (7 mmol/L TRIS-HCI, pH 7.5; 7 mmol/L MgCI,; 50 mmol/L NaCI; 100 pCi CY-~'P-~CTP). Radiolabeled DNA probe was separated from free "P-dCTP on a 12% native polyacrylamide gel as described3' and then eluted from polyacrylamide gel by overnight incubation in 1 mL of elution buffer ([OS mol/L ammonium acetate; 10 mmol/L magnesium acetate; 1 mmol/L EDTA; 0.1% [wt/vol] sodium dodecylsulfate [SDS]) with shaking (100 rpm). The eluted oligonucleotide probe was extracted three times with phenol/chloroform, precipitated by addition of one volume of 10 mol/L sodium acetate and three volumes of 100% ethanol, and the precipitates were collected by centrifugation (1 2,OOOg X 15 minutes) and redissolved in TE buffer. cDNA fragments corresponding to glycophorin A, PDGF-@, and GATA-1 were labeled with 32P using the random primer procedure.34 HEL and K562 cells were treated with or without PMA for 48 hours and lysed in lysis buffer ( I O mmol/L TRIS-HCI, pH 7.4; IO mmol/L NaC1; 3 mmol/L MgC1,; 0.5% [vol/vol] NP-40 detergent). Cleared lysates (12,OOOg X IO minutes) were fractionated on 12% SDS-polyacrylamide gels.35 The fractionated proteins were transferred onto nitrocellulose membrane as described. 36 The nitrocellulose blot was incubated with mouse monoclonal antiglycophorin A or anti-gpIIb IgG (2 pg/mL) in trisbuffered saline (TBS/T) (10 mmol/L TRIS-HCI, pH 7.5; 250 mmol/ L NaCI) containing 0.1% polysorbate 20 (Tween 20, IC1 Americas, Wilmington. DE) for I hour. rinsed with TBS/T buffer, and then incubated with goat-anti-mouse IgG conjugated with alkaline phosphatase. After further washing with TBS/T and TBS, the blot was developed by incubation with 5-bromo-4-chloro-3-indolylphosphate P-toluidine salt (BCIP) and nitroblue tetrazolium chloride (NRT) as recommended by the supplier.
RESULTS

PMA downre~idating glwophorin A e.~pression at the mRNA level.
It has been shown that y-globin gene expression is negatively regulated during megakaryocytic differentiation of K562 cells treated with PMA and that this downregulation of y-globin is caused by a decreased rate of transcription and an enhanced rate of the mRNA turnover.' On the other hand, PMA-induced megakaryocytic differentiation of HEL cells is not accompanied by an alteration in glycophorin A antigen levels.' We wondered if the failure to detect any change in glycophorin A antigen levels was due to the relatively slow turnover rate of the protein. Therefore, we measured the steady-state mRNA level of glycophorin A in HEL cells treated with or without PMA. Equal amounts of total RNA isolated from HEL cells using the guanidine/ HCI procedure was analyzed by dot blotting. The RNA dot blot was probed with a "P-labeled cDNA fragment of gly-cophorin A. washed as described in the Materials and Methods section, and autoradiographed. The results ( Fig IA) showed that compared with the untreated control (lane I), PMA (lane 2), but not okadaic acid (lane 3), dramatically downregulated glycophorin A mRNA expression. Hemin plus ACL is known to increase erythroid differentiation for K562 cells. 6 We observed that in the presence of ACL, hemin approximately doubled glycophorin A expression in HEL cells (lane 6) as quantitated by densitometric scanning. which is similar to that observed with K562 cells (Fig 2A. lane 6) . However, hemin did not affect the PMA-induced downregulation of glycophorin A expression (lane 4), nor did it enhance glycophorin A expression in the presence of okadaic acid (lane 5). Although PMA has been shown to induce a megakaryocytic differentiation of HEL cells? it did not induce expression of PDGF-p, a megakaryocytic/platelet marker ( Fig  IB, lane 2) . Consistent with previous reports." PMA caused a fourfold induction in PDGF-P expression in K562 cells For personal use only. on May 31, 2017. by guest www.bloodjournal.org From ( Fig 2B. lane 2) . whereas glycophorin A expression was essentially turned off in PMA-treated cells (Fig 2A, lane 2) .
We further analyzed glycophorin A expression at the protein level by Western blotting. Equal amounts of protein lysates from HEL or K562 cells treated with or without PMA were fractionated on 12% SDS-polyacrylamide gels and the fractionated proteins transferred onto nitrocellulose membrane. The protein blot was then probed with mouse monoclonal anti-human glycophorin A IgG, followed by probing with goat-anti-mouse IgG conjugated with alkaline phosphatase. Both K562 and HEL cells expressed considerable amounts ofglycophorin A antigen (Fig 3. panel B, arrow G) and that the levels of glycophorin A antigen are not significantly affected by PMA treatment (Fig 3B. lanes 2 and 4) compared with those of the untreated controls (lanes I and 3). However, when the protein lysates were analyzed for the megakaryocytic marker gpllb expression, we found that K562 cells did not express any detectable levels ofthis antigen before ( Fig 3A. lane I ) or after (lane 2) PMA treatment. On the other hand. HEL cells constitutively express gpllb antigen and levels of antigen expression were enhanced following PMA treatment ( Fig 3A, lane 4) compared with that of the untreated control (lane 3).
PMA downrcgii1atc.s GA TA-I c>xpre.ssion in H E L cc1l.s. We showed that PMA-induced megakaryocytic differentiation was characterized by the downregulation of the erythrocytic marker glycophorin A mRNA expression (Fig 1) and by an increased expression of megakaryocytic antigen glycoprotein Ilb (Fig 3A) . In addition, because glycophorin A and other erythroid-specific genes contain a GATA motifls) at their 5' flanking and because the GATA-I transcription factor is involved in regulating expression of these genes." we asked whether the downregulation of glycophorin A expression in HEL cells by PMA was coupled with a reduction in GATA-I DNA-binding activity and/or its mRNA expression. Nuclear proteins from HEL cells treated with or without PMA were extracted and equal amounts (IO pg) of the extracted proteins were analyzed for GATA-I activity with a gel mobility shift assay. It was observed (Fig 4) that PMA treatment caused a significant reduction in nuclear GATA-I activity (lane 6) compared with that of the untreated control (lane 5). This detected GATA-I activity is specific. The GATA-I factor has been characterized as a nuclear protein that participates in regulating erythroid specific gene (lanes 1 and 3) or PMA (lanes 2 and 4) expression during erythrocytic and perhaps megakaryocytic differentiation. However. we have recently observed that this transcription factor is also present in a relative high level in cytosol of K562 cells and the detected cytosolic GATA-I activity is not the result of nuclear protein contamination, as determined by tracking other protein markers in both cytosolic and nuclear compartments (W. Dai, unpublished data, June 1992). We asked whether the downregulation of nuclear GATA-I in HEL cells after PMA treatment was simply caused by the translocation of GATA-1. To answer the question. the cytosolic fraction of HEL cells treated with or without PMA was isolated and equal amounts of proteins (30 pg) were analyzed for GATA-I activity with gel mobility shift assays. The results shown in Fig 5 indicate that there existed significant amounts of GATA-I activity in the untreated cytosol of HEL cells ( Fig 5A, lane 1, arrow) . Similar to what was observed with nuclear extracts, GATA-I activity in cytosol was also downregulated by PMA ( Fig 5A, lane 2) . Lane 3 in Fig 5A represent GATA-I activity of nuclear extracts from the untreated HEL cells. To confirm that the detected cytoplasmic GATA-I activity in HEL cells is not the result of nuclear contamination. we also analyzed the untreated cytoplasmic proteins for SP-I activity, because SP-I is a known nuclear transcription factor. Results shown in Fig 5B indicated that there existed no detectable levels of SP-I activity in the cytosolic fraction of HEL cells ( Fig 5B. lane I) , whereas nuclear extracts contained high levels of this activity ( Fig 5B, lane 2, arrow) . The detected SP-I activity was specific as shown by homologous ( Fig 5B, lane 3) and heterologous DAI AND MURPHY competition ( Fig 5B, lane 4) . It was noted that some "nonspecific" bands were also competed out with unlabeled oligonucleotide fragment containing SP-I binding motif ( Fig  5B, lane 3) , and this is most likely caused by some protein factors that also specifically recognize a part of DNA sequence in the oligonucleotide fragment. In fact, sequence analysis showed that cis-acting elements such as AP-2 also are present in the oligonucleotide fragment.
Because posttranslational modifications such as phosphorylation/dephosphorylation regulate DNA-binding activities as well as transactivation or transrepression potentials For personal use only. on May 31, 2017. by guest www.bloodjournal.org From of many transcription factors,3s we wondered if PMA downregulated only GATA-I activity in HEL cells. We next determined if PMA also affected steady-state levels of GATA-I mRNA. Total RNA ( 1 5 pg) isolated from HEL cells treated with or without PMA for 2 days were fractionated on a formaldehyde agarose gel and transferred to a nitrocellulose membrane. The RNA blot was then hybridized with a GATA-I-specific cDNA probe labeled with 3zP, washed following hybridization, and autoradiographed. It was shown ( Fig 6) that HEL cells constitutively expressed considerable levels of GATA-I mRNA (lane I ) that were enhanced in the presence of hemin plus ACL (lane 3). However, in the presence of PMA, the GATA-I mRNA level was significantly reduced (lane 2), correlating very well with the downregulated GATA-1 DNA-binding activity (Figs 4, 5) . Lanes 4 to 6 were total RNA fractionated on a formaldehyde agarose gel and stained with ethidium bromide before being transferred to the nitrocellulose membrane, indicating that approximately same amounts of RNA were used for analysis.
DISCUSSION
Several human erythroleukemia or megakaryocytic leukemia cell lines can be induced by PMA to acquire multiple markers of the megakaryocyte/platelet phen~type.'.~.~~ The induction of these marker genes is accompanied by an increase in their cytoplasmic content and cause cells to exhibit features of morphologic mat~ration.~' In the present study, we have shown that in HEL cells, the increased expression of megakaryocytic marker (Fig 3) is associated with negative expression of both the glycophorin A mRNA (Fig 1) and the GATA-I mRNA and its DNA-binding activity (Figs 4, 6) , indicating that PMA initiates a shift of phenotype during megakaryocytic terminal differentiation. To date, GATA-1 is the only well-characterized transcription factor mediating cell-specific gene expression in developing erythroid progenitors." Because GATA-I and glycophorin A, belonging to different hierarchies, are both affected by PMA treatment, we interpret that PMA acts directly to downregulate GATA-1 activity, which in turn may affect glycophorin A expression.
Several studies by other groups support our interpretation that downregulation of GATA-I activity is responsible for a I loss of the erythroid phenotype in HEL cells. It has been shown4' that human carbonic anhydrase I (HCAI), an erythroid-specific gene product, contains several potential GATA factor-binding motifs at its 5' flanking regions; when two of these sites are placed upstream of a minimal eukaryotic promoter, they confer upregulation of a reporter gene expression in erythroid cells but not in nonerythroid cells:o indicating the importance of these GATA sequences in mediating HCAI expression. When HEL cells are treated with TPA, HCAI expression as determined by measuring its transcripts are greatly diminished when compared with those in the untreated cells.40 In addition, it has been reported4' that PMA induces megakaryocytic differentiation and decreases the level of EpoR mRNA in human megakaryoblastic UT-7 cells. After 24 hours of PMA treatment, EpoR mRNA downregulation is correlated with a significant drop of the GATA-I mRNA level and DNA-binding activity,'" suggesting that the PMAinduced decline in EpoR gene expression is linked to
Although the role of GATA-I in regulating megakaryopoiesis is yet to be documented. our studies suggest that GATA-I may not be essential for upregulation of gpllb antigen levels and perhaps other megakaryocyte/platelet markers. However, it is possible that the observed increase in the gpIlb antigen level is caused by mechanisms of an enhanced translation rate and/or a decreased turnover rate of the protein rather than an increased transcription rate. On the other hand, because there still exist basal levels ofGATA-I mRNA ( Fig  6, lane 2) and the GATA-I DNA-binding activity in PMAtreated HEL cells (Fig. 5, lane 6) , we cannot exclude the possible role that low levels of GATA-I expression are sufficient for regulating gpllb or other megakaryocyte marker expression in HEL cells. Because point mutation experiments that abolish binding of GATA-I result in a 70% decrease in the transcriptional activity of a megakaryocytic promoterz6 and because the mast cell-specific protein carboxypeptidase A gene is also dependent on GATA-binding factors:* it is still likely that megakaryocyte-specific genes may be regulated by GATA-I or other GATA-binding factor(s). In addition, because the EpoR gene, whose expression depends on GATA-I a~tivity:~ is turned on in both erythroid cells and mega-GATA-1. 1 2 3 
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For personal use only. on May 31, 2017. by guest www.bloodjournal.org From karyocyte~,'~ the low levels of GATA-1 m R N A and its DNAbinding activity in H E L cells undergoing megakaryocytic differentiation may mediate the expression of genes shared by these two lineages.
It is interesting to observe that GATA-I expression and its DNA-binding activity is inversely correlated with that of AP-I activity during H E L cell differentiation ( Fig 5) . It has been long speculated that a relationship exists between these two transcription factors in regulating erythroid gene expression because the GATA motif and 12-0-tetradecanoyl-phorbol-13-acetate (TPA)-responsive &-acting element (TRE) are consistently present at loci known to be important for establishing the erythroid program.2' Recently, in vivo dimethyl sulfate footprinting analysis by Orkin's group44 showed that a single AP-I/NF-E2 site as well as four sites of GATA within the hypersensitive site 3 of the &globin locus control region were recognized by protein factors present in erythroid cells, strongly suggesting that the AP-I and GATA-1 are essential trans-acting factors involved in regulating globin gene expression during erythroid development. Because NF-E2 is not proteolytic product of AP-1 , 26 and because AP-I activity is upregulated during megakaryocytic differentiation of H E L cells (Fig 4, lane 2) , we propose that NF-E2 is one of the essential factors for upregulating erythrocytic gene expression, and that AP-1 may compete for AP-l/NF-E2 site with NF-E2 and negatively regulate their gene expression.
Consistent with previous studies,8 we did not observe a significant decrease i n steady-state levels of glycophorin A antigen in H E L cells treated with PMA. This relatively constant level of glycophorin A protein is very likely caused by its high expression and a slow turnover rate of the antigen in HEL cells. On the other hand, one predicts that the PMAinduced decrease in the glycophorin A m R N A level should be coupled with a drop in the rate of new protein synthesis. In fact, using metabolic labeling with [35S]methionine a n d immunoprecipitation, it has been demonstrated that a threefold reduction is observed in glycophorin A biosynthesis in K562 cells treated with PMA for only 4 hours.45 A similar reduction is also found in glycophorin A protein synthesis in PMA-treated H E L cells.44
